LumiraDx Ltd

LumiraDX Ltd. is a next-generation point of care diagnostics company, which engages in the provision of an innovative diagnostic platform that supports a menu of tests with lab-comparable performance at the point of care. The firm's diagnostic testing solutions are being deployed by governments and healthcare institutions across laboratories, urgent care, physician offices, pharmacies, schools, and workplaces to screen, diagnose, and monitor wellness as well as disease. It also has a comprehensive portfolio of COVID-19 testing solutions from the lab to point of need. The company was founded by Ronald Zwanziger, David Scott, and Jerry McAleer in 2014 and is headquartered in London, the United Kingdom.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q1 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

LumiraDX Ltd. is a point of care diagnostics company, which engages in the provision of a diagnostic platform that supports tests with lab-comparable performance at the point of care. The company was founded by Ronald Zwanziger, David Scott, and Jerry McAleer in 2014 and is headquartered in Waltham, MA.

LumiraDx Limited (LMDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will LumiraDx Limited (LMDX) Report Negative Q1 Earnings? What You Should Know

LONDON, April 24, 2023 (GLOBE NEWSWIRE) -- LumiraDx Limited (Nasdaq: LMDX)(the “Company”) today announced that it has received notification (the “Notification”) from The Nasdaq Stock Market LLC that it is not in compliance with the minimum bid price requirement in Nasdaq Listing Rule 5450(a)(1) for continued listing on the Nasdaq Global Market, since the closing bid price for the Company's common shares on the Nasdaq Global Market was below US$1.00 for 30 consecutive trading days. Nasdaq Listing Rule 5450(a)(1) requires the common shares to maintain a minimum bid price of US$1.00 per share (the “Minimum Bid Requirement”), and Nasdaq Listing Rule 5810(c)(3)(A) provides that failure to meet such requirement exists if the deficiency continues for a period of 30 consecutive business days.

LumiraDx Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency

LONDON, April 06, 2023 (GLOBE NEWSWIRE) -- LumiraDx Limited (Nasdaq: LMDX), a leading global provider of point-of-care diagnostics testing solutions, today announced its Strategic Refocus and Cost Restructuring Program aimed at reducing its scale and operations to pre-pandemic levels and to further evolve LumiraDx into an agile organization with a clear focus on the areas with the greatest potential.

LumiraDx Announces Strategic Refocus and Cost Restructuring Program

LumiraDx Limited (NASDAQ:LMDX ) Q4 2022 Earnings Conference Call March 21, 2023 8:30 AM ET Company Participants Melissa Garcia - Vice President Corporate Counsel Ron Zwanziger - Chairman and CEO Dorian LeBlanc - Chief Financial Officer Veronique Ameye - Deputy CEO Conference Call Participants Jeffrey Cohen - Ladenburg Tallman Matt Sykes - Goldman Sachs Mark Massaro - BTIG Andrew Cooper - Raymond James Operator Good day and thank you for standing by. Welcome to the LumiraDx Fourth Quarter 2022 Earnings Conference Call.

LumiraDx Limited (LMDX) Q4 2022 Earnings Call Transcript

LumiraDx Limited (LMDX) delivered earnings and revenue surprises of -68.42% and 7.06%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

LumiraDx Limited (LMDX) Reports Q4 Loss, Tops Revenue Estimates

LONDON, March 21, 2023 (GLOBE NEWSWIRE) -- LumiraDx Limited (NASDAQ: LMDX), a next-generation point of care (POC) diagnostics company, today announced financial results for its fourth quarter and full year ended December 31, 2022.

LumiraDx Reports Fourth Quarter and Full Year 2022 Results

LONDON, March 14, 2023 (GLOBE NEWSWIRE) -- LumiraDx Limited (Nasdaq: LMDX), a next-generation point of care (POC) diagnostics company, announced it will release its fourth quarter and full year 2022 financial results on Tuesday, March 21st, 2023. On the day of the release, LumiraDx will host a conference call and webcast at 8:30 AM Eastern Time to review the financial results and business highlights.

LumiraDx to Announce Fourth Quarter and Full Year 2022 Financial Results and Host Quarterly Conference Call on March 21

LONDON, March 03, 2023 (GLOBE NEWSWIRE) -- LumiraDx Limited (Nasdaq: LMDX) (the “Company”) today announced that Chief Financial Officer, Dorian LeBlanc, will be presenting at the Raymond James Institutional Investors Conference on Tuesday, March 7th, 2023 at 4:35pm ET. Webcast link below.

LumiraDx to Present at Raymond James Institutional Investors Conference

LONDON, Feb. 17, 2023 (GLOBE NEWSWIRE) -- LumiraDx Limited (Nasdaq: LMDX) (the “Company”) today announced that it has received confirmation from The Nasdaq Stock Market LLC (“Nasdaq”) that it has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5450(a)(1).

LumiraDx Regains Compliance with Nasdaq Continued Listing Requirements

LONDON, Jan. 31, 2023 (GLOBE NEWSWIRE) -- LumiraDx Limited (Nasdaq: LMDX), a next-generation point of care diagnostics company, today announced it has commenced commercial shipment of its point of care NT-proBNP test to aid in the diagnosis of CHF across Europe.

LumiraDx Announces Commercial Shipment of its Point of Care NT-proBNP Test in Europe, Supporting Heart Health Checks in UK

LONDON, Jan. 31, 2023 (GLOBE NEWSWIRE) -- LumiraDx Limited (Nasdaq: LMDX)(the “Company”) today announced that it has received notification (the “Notification”) from The Nasdaq Stock Market LLC that it is not in compliance with the minimum bid price requirement in Nasdaq Listing Rule 5450(a)(1) for continued listing on the Nasdaq Global Market, since the closing bid price for the Company's common shares on the Nasdaq Global Market was below US$1.00 for 30 consecutive trading days. Nasdaq Listing Rule 5450(a)(1) requires the common shares to maintain a minimum bid price of US$1.00 per share (the “Minimum Bid Requirement”), and Nasdaq Listing Rule 5810(c)(3)(A) provides that failure to meet such requirement exists if the deficiency continues for a period of 30 consecutive business days.

LumiraDx Announces Receipt of Nasdaq Notification Letter Regarding Minimum Bid Price Deficiency

Company receives $14.2M in grants from the Bill & Melinda Gates Foundation to support the TB test's ongoing development and future launch into developing countries Company receives $14.2M in grants from the Bill & Melinda Gates Foundation to support the TB test's ongoing development and future launch into developing countries

LumiraDx Announces New Investment for Ongoing Development of its Point of Care Molecular Tuberculosis Test

LumiraDx shares these and other findings from its second annual U.S. survey “Point of Care Diagnostics: A Clinician's View” LumiraDx shares these and other findings from its second annual U.S. survey “Point of Care Diagnostics: A Clinician's View”

Latest Clinicians' U.S. Survey Identifies Point of Care Testing (POCT) as a Way to Address Healthcare Bandwidth Pressures and Anticipates Future Growth of POCT in Community Testing Centers

LumiraDx shares these and other findings from its first annual U.K. survey “Point of Care Diagnostics: A Clinicians View” LumiraDx shares these and other findings from its first annual U.K. survey “Point of Care Diagnostics: A Clinicians View”

Point of Care (POC) Survey Reveals Majority of U.K. Clinicians Endorse Climate Benefits of POC Through Reduction of Carbon Emissions and Anticipate Future Growth of POC Testing to Come from Community Settings

Now Available in Europe, parts of the Middle East, Asia, Latin America, and Africa  Early customers include GP offices and other community-based healthcare settings Latest figures, released as part of World Diabetes Day, reveal that 1 in 10 adults are now living with diabetes and nearly half are undiagnosed1 The LumiraDx HbA1c test is designed to address the growing clinical need for accessible and reliable HbA1c testing in community-based healthcare settings such as primary care, diabetes clinics, rural clinics, retail pharmacy & other decentralised healthcare settings The actively controlled microfluidic immunoassay is run on the highly portable LumiraDx Platform and designed for near-patient testing with connected results in under seven minutes The addition of HbA1c to the rapidly growing LumiraDx test menu, enables the consolidation of multiple instruments to a single, next-generation point of care Platform; all with a common workflow LONDON , Nov. 14, 2022 /PRNewswire/ -- LumiraDx Limited (Nasdaq: LMDX), a next-generation point of care diagnostics company, today announced the continued commercial expansion of its HbA1c test, for professional use across multiple care settings. Used alongside the LumiraDx Platform, the test monitors known diabetic patients' HbA1c levels and also serves as an aid in screening and identifying patients who may be at risk for developing diabetes.

LumiraDx Continues Commercial Expansion of its Rapid Microfluidic Immunoassay HbA1c Test

LumiraDx Limited (NASDAQ:LMDX ) Q3 2022 Results Conference Call November 9, 2022 8:00 AM ET Company Participants Colleen McMillen - Vice President, Communications Ron Zwanziger - Chairman and CEO Dorian LeBlanc - Chief Financial Officer Conference Call Participants Jeffrey Cohen - Ladenburg Tallman Andrew Cooper - Raymond James Operator Good day and thank you for standing by. Thank you for joining LumiraDx Third Quarter 2022 Earnings Conference Call.

LumiraDx Limited (LMDX) Q3 2022 Earnings Call Transcript

LumiraDx Limited (LMDX) delivered earnings and revenue surprises of -56.67% and 46.15%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

LumiraDx Limited (LMDX) Reports Q3 Loss, Tops Revenue Estimates

Progress on Near-Term Growth Opportunities and Cost Savings Progress on Near-Term Growth Opportunities and Cost Savings

LumiraDx Reports Third Quarter 2022 Results

LONDON, Nov. 02, 2022 (GLOBE NEWSWIRE) -- LumiraDx Limited  (Nasdaq: LMDX), a next-generation point of care (POC) diagnostics company, announced it will release its third quarter financial results on Wednesday, November 9th, 2022. On the day of the release, LumiraDx will host a conference call and webcast at 8:00 AM Eastern Time to review the financial results and business highlights.

LumiraDx to Announce Third Quarter Financial Results and Host Quarterly Conference Call on November 9

The research company recognizes LumiraDx for uniquely leveraging its technology to meet customers' needs and capitalizing on new growth opportunities The research company recognizes LumiraDx for uniquely leveraging its technology to meet customers' needs and capitalizing on new growth opportunities

LumiraDx named by Frost & Sullivan as the 2022 Europe Technology Innovation Leader in the Microfluidics Point of Care Diagnostics Industry

Testing Times Report reflects expert opinion that “Supporting more widespread use of rapid diagnostic technology should be a central aim of efforts to tackle the next hidden pandemic” Testing Times Report reflects expert opinion that “Supporting more widespread use of rapid diagnostic technology should be a central aim of efforts to tackle the next hidden pandemic”

LumiraDx Partners with British In Vitro Diagnostics Association to Report on the Role of Rapid Diagnostics in Tackling Antimicrobial Resistance

LumiraDx Limited (NASDAQ:LMDX ) Q2 2022 Earnings Conference Call August 18, 2022 8:00 AM ET Company Participants Colleen McMillen - Vice President, Communications Ron Zwanziger - Chairman and CEO Dorian LeBlanc - Chief Financial Officer Pooja Pathak - Chief Product Officer Conference Call Participants Vijay Kumar - Evercore ISI Jeffrey Cohen - Ladenburg Mark Massaro - BTIG Operator Good day. And welcome to the LumiraDx Second Quarter 2022 Earnings Call.

LumiraDx Limited's (LMDX) CEO Ron Zwanziger on Q2 2022 Results - Earnings Call Transcript

Strong Pipeline Progress and Commercialization Priorities for Newly Authorized Products Strong Pipeline Progress and Commercialization Priorities for Newly Authorized Products

LumiraDx Reports Second Quarter 2022 Results

LONDON, Aug. 11, 2022 (GLOBE NEWSWIRE) -- LumiraDx Limited  (Nasdaq: LMDX), a next-generation point of care (POC) diagnostics company, announced it will release its second quarter financial results on Thursday, August 18th, 2022. On the day of the release, LumiraDx will host a conference call and webcast at 8:00 AM Eastern Time to review the financial results and business highlights.

LumiraDx to Announce Second Quarter Financial Results and Host Quarterly Conference Call on August 18

The company announced the share price of its public stock offering.

News for LumiraDx Ltd Stock (LMDX)